Table 1 Univariate and multivariate analyses of clinicopathological characteristics and genetic alterations on overall survival.

From: BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer

Variable

Modality

N (%)

Univariate

Multivariate

5-y OS %

P-value

HR (95% CI)

P-value

Age (years)

<65

62 (56)

9.3

0.604

  

≥65

49 (44)

15.2

   

Sex

Male

66 (59)

5.0

0.104

  

Female

45 (41)

24.0

   

Tumor size (mm)

<50

36 (32)

0.0

0.258

  

≥50

75 (68)

14.1

   

Pre-operative CEA (ng/ml)

<200

85 (77)

13.8

0.338

  

≥200

26 (23)

5.1

   

Primary tumor site

Right-sided

34 (31)

9.7

0.157

  

Left-sided

77 (69)

13.0

   

Histopathological grade

G1, 2

78 (70)

14.2

0.001

1.00

 

G3

33 (30)

6.7

 

1.30 (1.01–1.68)

0.041

T category

T2, 3

47 (42)

0.0

0.059

  

T4

64 (58)

10.4

   

N category

N0

15 (14)

24.1

0.036

  

N1

96 (86)

9.6

   

M category

M1a

56 (50)

15.6

0.511

  

M1b

55 (50)

9.8

   

Liver metastasis

Absent

23 (21)

21.8

0.139

  

Present

88 (79)

8.7

   

Lung metastasis

Absent

77 (69)

11.8

0.824

  

Present

34 (31)

12.2

   

Peritoneal metastasis

Absent

89 (80)

13.5

0.116

  

Present

22 (20)

5.5

   

Liver-limited metastasis

Absent

64 (58)

11.9

0.815

  

Present

47 (42)

11.6

   

Number pf metastatic sites

1

64 (58)

16.0

0.753

  

≥2

47 (42)

8.7

   

Residual tumor

R0

45 (41)

19.2

<0.001

0.54 (0.33–0.88)

0.013

R2

66 (59)

6.5

 

1.00

 

APC

Wild-type

19 (17)

19.1

0.399

  

Mutant

92 (83)

9.5

   

ARID1A

Wild-type

96 (86)

11.7

0.725

  

Mutant

15 (14)

16.1

   

ATM

Wild-type

99 (89)

11.4

0.676

  

Mutant

12 (11)

11.1

   

BRAF

Wild-type

98 (88)

12.7

<0.001

1.00

 

Non-V600E

6 (5)

33.3

 

1.52 (0.54–4.30)

0.424

V600E

7 (6)

0.0

 

3.47 (1.45–8.29)

0.005

FBXW7

Wild-type

94 (85)

9.3

0.603

  

Mutant

17 (15)

25.7

   

KRAS

Wild-type

72 (65)

12.0

0.348

  

Mutant

39 (35)

13.5

   

PIK3CA

Wild-type

97 (87)

12.8

0.082

  

Mutant

14 (13)

0.0

   

PTEN

Wild-type

71 (64)

15.9

0.677

  

Mutant

40 (36)

7.4

   

SMAD2

Wild-type

96 (86)

12.9

0.288

  

Mutant

15 (14)

6.7

   

SMAD4

Wild-type

73 (66)

15.3

0.281

  

Mutant

38 (34)

7.3

   

SRC

Wild-type

97 (87)

14.2

0.035

1.00

 

Mutant

14 (13)

0.0

 

1.99 (1.10–3.59)

0.023

TP53

Wild-type

26 (23)

17.5

0.483

  

Mutant

85 (77)

10.3

   
  1. Only genes altered in more than 10% of patients (n = 12) are noted in this table, but all 31 genes altered in more than 5% of patients were evaluated.
  2. 95% CI 95% confidence interval, HR hazard ratio, OS overall survival.